Back to news

Veradermics Slides as Investors Digest Recent Trial Updates and New Filing

Investivoq PriceTracker

Veradermics (MANE) is down 10.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is a sell-the-news reaction after Veradermics released fresh clinical updates and quarterly results earlier this week. This could be because the company’s recent announcements were positive, but they were paired with another quarterly net loss and a new filing that disclosed planned insider stock-sale programs, which may have encouraged traders to lock in gains after a sharp run in the shares.

Details:

  • Veradermics said on November 9 that its 12-month Study ‘302’ data for VDPHL01 in male pattern hair loss were positive, with continued hair-count gains and no treatment-related serious adverse events or cardiac-related adverse events of special interest.
  • On November 10, the company reported third-quarter 2026 results showing cash, cash equivalents, and marketable securities of $798.4 million, which management said should fund operations into 2030 through multiple readouts and a potential launch.
  • The same quarterly update showed a net loss of $21.0 million for the third quarter and higher general and administrative expense tied in part to commercial readiness and stock-based compensation.
  • Veradermics’ 10-Q also disclosed new Rule 10b5-1 trading plans adopted by two executives covering potential sales of common stock beginning in December 2026, a detail that may have weighed on sentiment even though the plans are prearranged.

    • Sources:

    SEC, Veradermics, Yahoo Finance

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $MANE Insider Trading Activity

    MANE Insider Trades

    $MANE insiders have traded $MANE stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.

    Here’s a breakdown of recent trading of $MANE stock by insiders over the last 6 months:

    • CAPITAL, LLC MONTANOVA has made 0 purchases and 2 sales selling 750,000 shares for an estimated $80,437,500.
    • JOHN W CHILDS has made 0 purchases and 3 sales selling 100,000 shares for an estimated $10,711,700.
    • REID ALEXANDER WALDMAN (Chief Executive Officer) has made 0 purchases and 5 sales selling 67,500 shares for an estimated $7,280,712.
    • TIMOTHY AUGUST DURSO (Chief Technical Officer) has made 0 purchases and 5 sales selling 43,500 shares for an estimated $4,690,004.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive MANE Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $MANE Hedge Fund Activity

    We have seen 142 institutional investors add shares of $MANE stock to their portfolio, and 49 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • DEEP TRACK CAPITAL, LP added 1,500,000 shares (+300.0%) to their portfolio in Q2 2026, for an estimated $184,410,000
    • BLACKROCK, INC. added 1,311,180 shares (+464.0%) to their portfolio in Q2 2026, for an estimated $161,196,469
    • JPMORGAN CHASE & CO added 1,207,123 shares (+103.6%) to their portfolio in Q3 2026, for an estimated $146,339,521
    • D. E. SHAW & CO., INC. added 1,013,643 shares (+inf%) to their portfolio in Q2 2026, for an estimated $124,617,270
    • MAVERICK CAPITAL LTD added 789,980 shares (+inf%) to their portfolio in Q2 2026, for an estimated $97,120,141
    • JENNISON ASSOCIATES LLC added 606,897 shares (+428.1%) to their portfolio in Q2 2026, for an estimated $74,611,917
    • ADAGE CAPITAL PARTNERS GP, L.L.C. removed 550,294 shares (-50.0%) from their portfolio in Q2 2026, for an estimated $67,653,144

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $MANE Analyst Ratings

    Wall Street analysts have issued reports on $MANE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • Needham issued a "Buy" rating on 06/02/2026

    To track analyst ratings and price targets for $MANE, check out Investivoq's $MANE forecast page.

    $MANE Price Targets

    Multiple analysts have issued price targets for $MANE recently. We have seen 4 analysts offer price targets for $MANE in the last 6 months, with a median target of $135.5.

    Here are some recent targets:

    • Roger Song from Jefferies set a target price of $182.0 on 07/07/2026
    • Rami Katkhuda from LifeSci Capital set a target price of $135.0 on 06/16/2026
    • Serge Belanger from Needham set a target price of $136.0 on 06/02/2026
    • Geoff Meacham from Citigroup set a target price of $135.0 on 05/18/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.